Amgen Inc (AMGN): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Amgen ( AMGN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 2.5%. By the end of trading, Amgen fell $4.62 (-4.1%) to $109.13 on heavy volume. Throughout the day, 5,156,258 shares of Amgen exchanged hands as compared to its average daily volume of 3,261,900 shares. The stock ranged in price between $108.58-$112.64 after having opened the day at $111.70 as compared to the previous trading day's close of $113.75. Other companies within the Health Care sector that declined today were: Mast Therapeutics ( MSTX), down 40.8%, Acura Pharmaceuticals ( ACUR), down 19.8%, Dehaier Medical Systems ( DHRM), down 14.2% and Agios Pharmaceuticals ( AGIO), down 11.5%.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $79.6 billion and is part of the drugs industry. Shares are up 22.5% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Catalyst Pharmaceutical Partners ( CPRX), up 41.5%, Hi-Tech Pharmacal ( HITK), up 22.1%, GW Pharmaceuticals PLC ADR ( GWPH), up 17.5% and Stereotaxis ( STXS), up 9.7%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback